In the open-label randomised phase 3 CANDOR trial, the addition of anti-CD38 antibody daratumumab to carfilzomib and dexamethasone reduced the risk of disease progression or death by 37% compared with carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma (MM).
Prof. Saad Z. Usmani (UNC-Chapel Hill School of Medicine, USA) presented the initial results of the trial, which randomised 466 patients (2:1 ratio) with relapsed/refractory MM previously treated with 1 to 3 prior therapies to either daratumumab + carfilzomib/dexamethasone (n=312) or carfilzomib/dexamethasone alone (n=154) . The primary endpoint of this study was progression-free survival (PFS). Key secondary endpoints were overall response rate, minimal residual disease-negative status, complete response rate at 12 months, overall survival (OS), duration of response, and safety.
The median PFS...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Aspirin plus DOAC is not better than a DOAC alone Next Article
Arginine supplements help against sickle cell disease pain »
Table of Contents: ASH 2019
Sickle Cell Disease
Plenary Scientific Session
CAR T and Beyond
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.